Cystic Fibrosis Gastrointestinal Disease
6
1
4
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
33%
2 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (6)
Gastrointestinal Response of Pediatric Cystic Fibrosis Patients on Mediterranean Diet
Cardiac Structure and Function in Patients with Cystic Fibrosis
Intestinal Inflammation in CF Patients
Cystic Fibrosis and Gut Dysmotility: The Effect of Polyethylene Glycol (PEG) on Intestinal Transit
Real World Clinical Outcomes With Novel Modulator Therapy Combinations in People With CF (RECOVER)
Phase 2 Combination Study With Escalating Doses of MS1819-SD on Top of a Stable Dose of PPEs